Sea Lane Biotechnologies LLC
Assembling antibodies with modular components, by the billions
This article was originally published in Start Up
Sea Lane Biotechnologies LLC’s original goal was to leverage the immunological repertoire of flu epidemic survivors by harvesting bone marrow and screening for natural antibodies that could then be developed into drugs, but the human-derived antibodies that Sea Lane gathered in its early days contributed to a new technology platform. Sea Lane thinks its technology, called ConCIRT, for Contextual Immune Repertoire Technology, will prove capable of generating novel treatments for cancer and potentially other non-infectious diseases.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.